Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.
immunotherapy
overall survival
prostate cancer
safety
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
01 12 2019
01 12 2019
Historique:
received:
19
12
2018
revised:
12
07
2019
accepted:
17
07
2019
pubmed:
5
9
2019
medline:
4
6
2020
entrez:
5
9
2019
Statut:
ppublish
Résumé
The large registry, PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (PROCEED)(NCT01306890), evaluated sipuleucel-T immunotherapy for asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). PROCEED enrolled patients with mCRPC receiving 3 biweekly sipuleucel-T infusions. Assessments included overall survival (OS), serious adverse events (SAEs), cerebrovascular events (CVEs), and anticancer interventions (ACIs). Follow-up was for ≥3 years or until death or study withdrawal. In 2011-2017, 1976 patients were followed for 46.6 months (median). The median age was 72 years, and the baseline median prostate-specific antigen level was 15.0 ng/mL; 86.7% were white, and 11.6% were African American. Among the patients, 1902 had 1 or more sipuleucel-T infusions. The median OS was 30.7 months (95% confidence interval [CI], 28.6-32.2 months). Known prognostic factors were independently associated with OS in a multivariable analysis. Among the 1255 patients who died, 964 (76.8%) died of prostate cancer (PC) progression. The median time from the first infusion to PC death was 42.7 months (95% CI, 39.4-46.2 months). The incidence of sipuleucel-T-related SAEs was 3.9%. The incidence of CVEs was 2.8%, and the rate per 100 person-years was 1.2 (95% CI, 0.9-1.6). The CVE incidence among 11,972 patients with mCRPC from the Surveillance, Epidemiology, and End Results-Medicare database was 2.8%; the rate per 100 person-years was 1.5 (95% CI, 1.4-1.7). One or more ACIs (abiraterone, enzalutamide, docetaxel, cabazitaxel, or radium 223) were received by 77.1% of the patients after sipuleucel-T; 32.5% and 17.4% of the patients experienced 1- and 2-year treatment-free intervals, respectively. PROCEED provides contemporary survival data for sipuleucel-T-treated men in a real-world setting of new life-prolonging agents, which will be useful in discussing treatment options with patients and in powering future trials with sipuleucel-T. The safety and tolerability of sipuleucel-T in PROCEED were consistent with previous findings.
Sections du résumé
BACKGROUND
The large registry, PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (PROCEED)(NCT01306890), evaluated sipuleucel-T immunotherapy for asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).
METHODS
PROCEED enrolled patients with mCRPC receiving 3 biweekly sipuleucel-T infusions. Assessments included overall survival (OS), serious adverse events (SAEs), cerebrovascular events (CVEs), and anticancer interventions (ACIs). Follow-up was for ≥3 years or until death or study withdrawal.
RESULTS
In 2011-2017, 1976 patients were followed for 46.6 months (median). The median age was 72 years, and the baseline median prostate-specific antigen level was 15.0 ng/mL; 86.7% were white, and 11.6% were African American. Among the patients, 1902 had 1 or more sipuleucel-T infusions. The median OS was 30.7 months (95% confidence interval [CI], 28.6-32.2 months). Known prognostic factors were independently associated with OS in a multivariable analysis. Among the 1255 patients who died, 964 (76.8%) died of prostate cancer (PC) progression. The median time from the first infusion to PC death was 42.7 months (95% CI, 39.4-46.2 months). The incidence of sipuleucel-T-related SAEs was 3.9%. The incidence of CVEs was 2.8%, and the rate per 100 person-years was 1.2 (95% CI, 0.9-1.6). The CVE incidence among 11,972 patients with mCRPC from the Surveillance, Epidemiology, and End Results-Medicare database was 2.8%; the rate per 100 person-years was 1.5 (95% CI, 1.4-1.7). One or more ACIs (abiraterone, enzalutamide, docetaxel, cabazitaxel, or radium 223) were received by 77.1% of the patients after sipuleucel-T; 32.5% and 17.4% of the patients experienced 1- and 2-year treatment-free intervals, respectively.
CONCLUSIONS
PROCEED provides contemporary survival data for sipuleucel-T-treated men in a real-world setting of new life-prolonging agents, which will be useful in discussing treatment options with patients and in powering future trials with sipuleucel-T. The safety and tolerability of sipuleucel-T in PROCEED were consistent with previous findings.
Identifiants
pubmed: 31483485
doi: 10.1002/cncr.32445
pmc: PMC6856402
mid: NIHMS1043017
doi:
Substances chimiques
Tissue Extracts
0
sipuleucel-T
8Q622VDR18
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4172-4180Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA233585
Pays : United States
Organisme : Dendreon Pharmaceuticals LLC
Pays : International
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2019 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.
Références
N Engl J Med. 2013 Jan 10;368(2):138-48
pubmed: 23228172
Cancer Immunol Immunother. 2008 Sep;57(9):1381-90
pubmed: 18297282
Clin Cancer Res. 2011 Jul 1;17(13):4558-67
pubmed: 21558406
N Engl J Med. 2013 Jul 18;369(3):213-23
pubmed: 23863050
Cancer. 2009 Aug 15;115(16):3670-9
pubmed: 19536890
J Clin Oncol. 2006 Jul 1;24(19):3089-94
pubmed: 16809734
J Clin Oncol. 2014 Mar 1;32(7):671-7
pubmed: 24449231
Stroke. 2009 Jun;40(6):2276-93
pubmed: 19423857
J Clin Oncol. 2014 Oct 20;32(30):3436-48
pubmed: 25199761
Geriatrics (Basel). 2017 Jul 15;2(3):null
pubmed: 31011034
J Immunother Cancer. 2016 Dec 20;4:92
pubmed: 28031820
Clin Interv Aging. 2010 Sep 07;5:239-51
pubmed: 20852671
Cancer Immunol Immunother. 2013 Jan;62(1):137-47
pubmed: 22865266
N Engl J Med. 2014 Jul 31;371(5):424-33
pubmed: 24881730
Urology. 2013 Jun;81(6):1297-302
pubmed: 23582482
Lancet. 2010 Oct 2;376(9747):1147-54
pubmed: 20888992
Clin Cancer Res. 2017 May 15;23(10):2451-2459
pubmed: 27836866
Am J Epidemiol. 1990 Feb;131(2):373-5
pubmed: 2296988
Urology. 2017 Jun;104:150-159
pubmed: 28302580
Circulation. 2018 Mar 20;137(12):e67-e492
pubmed: 29386200
Lancet Oncol. 2012 Oct;13(10):983-92
pubmed: 22995653
N Engl J Med. 2010 Jul 29;363(5):411-22
pubmed: 20818862
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553
Clin Cancer Res. 2015 Sep 1;21(17):3862-9
pubmed: 25925891
Ann Oncol. 2015 Sep;26 Suppl 5:v69-77
pubmed: 26205393